



Pre-biologic Panel

Clear the way for your patients' biologic therapy with MACL's Pre-biologic Panel

The American College of Rheumatology (ACR) and American College of Gastroenterology (ACG) recommend screening for hepatitis B (HBV), hepatitis C (HCV), and latent TB infection in patients starting or currently receiving certain biologic agents.¹⁻³

What is the Pre-biologic Panel?

The Pre-biologic Panel from MACL includes ACR and ACG recommended testing to evaluate your patients for biologic or biosimilar therapy. The Panel includes:

- Hepatitis B screening
- Hepatitis C screening
- TB infection screening

Who should be tested and why?

- Patients who are using biologic agents such as Enbrel, Humira and Ocrencia in the treatment of rheumatoid arthritis, plaque psoriasis and inflammatory bowel disease, among other autoimmune diseases, should be tested.
- Such biologic treatments cause suppression of the immune system, making those patients more susceptible to infection. Thus testing for latent infections (tuberculosis) and other infections like hepatitis is recommended.



One simple test code (51871) includes all recommended lab tests.

Pre-biologic Panel



Mid America Clinical Laboratories' Pre-biologic Panel includes all of the guideline-recommended screenings for Pre-biologic therapy.

Pre-biologic/biosimilar Screen Panel with Reflexes	51871
Quantiferon-TB Gold Plus	51772
Hepatitis B Surface Antigen w/Confirmation	498
Hepatitis B Core AB Total	501
Hepatitis B Core Igm Antibodies	4848
Hepatitis B Surface Antibody Quantitative	8475
Hepatitis C Antibody w/Reflex to HCV RNA, PCR w/Reflex to Genotype, LIPA	94345

**Panel components may be ordered separately.*

Specimen Requirements:

1 Quantiferon - TB Gold Plus

3 Serum Separator (SST) Tubes



For more information about the Pre-biologic Panel, reach out to your Account Manager or contact us at sales@macl1.com

For more information about MACL, please visit us at www.maclonline.com